Malnutrition in Obesity: Screening the Patient a BMI Hides

Malnutrition in obesity is diagnosed at any BMI under the GLIM criteria, for example reduced muscle mass plus inflammation. The usual screens miss it: among older outpatients with a BMI of 25 or more, 58.8% of those malnourished passed the short-form screen.

A patient can carry excess fat and still lack the muscle, protein and micronutrients that recovery depends on. The screens most practices use were never designed to see that combination.

Malnutrition in obesity is a diagnosis the chart is built to miss. Every tool that opens the workup keys on weight loss and thinness, so the heavy patient sails through clean while sarcopenic wasting, active metaflammation and empty micronutrient stores go unrecorded.

The Global Leadership Initiative on Malnutrition (GLIM) never required a low weight. Its 2019 consensus asks for one phenotypic criterion (non-volitional weight loss, low BMI or reduced muscle mass) plus one etiologic criterion (reduced intake or assimilation, or inflammation and disease burden). Reduced muscle mass with inflammation is a complete diagnosis at any BMI. The 2025 five-year update kept that structure, left the choice of muscle-mass method to the technology a site has, allowed clinical judgment to satisfy the inflammation criterion, and named malnutrition in obesity as one of its open priorities. The criteria were never the obstacle. The habit of reading BMI as a proxy for nourishment is.

Why the usual screen clears the patient with obesity

GLIM is a two-step process: screen, then assess. The failure sits in the first step. Among 264 geriatric outpatients with a BMI of 25 or more, GLIM-defined malnutrition was present in 30.3% and sarcopenic obesity in 15.9%. More than half of the malnourished patients, 58.8%, were not at risk on the Mini Nutritional Assessment Short Form, the screen that would have sent them on to assessment. Among the patients that short form cleared, malnutrition ran 42.9% in those with sarcopenic obesity against 18.7% in those without. Where sarcopenic obesity and malnutrition coexisted, the odds ratio for frailty was 5.11, independent of age and comorbidity.

The pattern holds at higher weights. In adults with advanced knee osteoarthritis and a BMI of 35 or more, averaging a BMI of 42.4, 26.1% met GLIM criteria through low muscle mass on DXA plus elevated C-reactive protein, 26.1% had sarcopenic obesity, and 13% had both. These are the patients queued for joint replacement, and nothing in a weight-based intake flags them.

Sarcopenic obesity is a muscle diagnosis, not a weight diagnosis

The ESPEN and EASO consensus defines sarcopenic obesity as excess adiposity coexisting with low muscle mass or function. Screening begins with an elevated BMI or waist circumference plus suspicion of low muscle mass or function from risk factors, symptoms or a validated questionnaire. Diagnosis then runs in order: muscle function first, body composition second. Stage I carries no complications; Stage II carries complications linked to altered body composition or muscle dysfunction.

The consensus traces the condition to sedentary metabolic change, adipose tissue derangement, comorbid disease and aging, and those pieces run as a chain. Inflamed, insulin-resistant adipose tissue is the first driver, keeping a low-grade inflammatory signal running through the whole body. Muscle is the second: pain and fatigue cut movement, unloaded muscle wastes, and the patient loses glucose-disposal capacity while fat mass holds or grows. The third driver is economic. A food supply engineered around acellular carbohydrates and industrial seed oils sells calories far more readily than protein and micronutrients, so stored fuel rises while structural stores fall, and the scale records only the first half of that trade. Muscle and fat distribution also track neurodegenerative risk, which is set out in how body fat distribution relates to dementia.

The micronutrient layer follows inflammation

Among the first 200 adults evaluated for bariatric surgery at a hospital in Turin, 85.5% had at least one micronutrient deficiency, led by vitamin D at 74.5%, folate at 33.5% and iron at 32%. C-reactive protein was above 5 mg/L in 65% of them. After adjustment, elevated CRP carried an odds ratio of 5.84 for B12 deficiency and 4.02 for folate deficiency. Inflammation is therefore doing two jobs in the same patient: it satisfies a GLIM etiologic criterion, and it predicts which stores are empty. A high-sensitivity CRP on the draw both supports the diagnosis and tells you where to look next.

Why it matters in the operating room and on a GLP-1 prescription

Obesity alone is not the surgical hazard; muscle loss inside obesity is. Across 27,057 craniotomies in the American College of Surgeons NSQIP database, a sarcopenic-obese phenotype built from BMI and serum albumin carried an odds ratio of 2.28 for 30-day mortality, while the obese-replete phenotype showed no mortality increase at 1.06. Among 2,908 UK Biobank participants who went on to major abdominal cancer surgery, the 100 with sarcopenic obesity had a hazard ratio of 6.44 for death at 30 days and 3.61 at 90 days, with 27% longer hospital stays and 83% longer intensive care stays, yet no significant excess of complications (odds ratio 0.79).

That finding inverts the usual preoperative logic. These patients did not have more complications. They had less reserve to survive the ones they had. A complication audit will never surface them, a BMI will actively reassure you, and the obesity paradox is really a muscle story: fat with muscle behind it survived, fat without it did not. Only a measurement of muscle separates the two before the first incision.

Weight-loss therapy opens a second road into the same phenotype. In twenty randomized trials with 15,782 participants whose body composition was measured by DXA or MRI, lean mass made up 25% to 39% of the weight lost on incretin agonists, 35.2% on semaglutide, and a comparable 26.2% with lifestyle intervention alone. Lifestyle plus resistance training had the smallest lean share, 17.5%. A chart tracking weight, A1c and blood pressure can improve on every line while a patient with marginal muscle crosses into sarcopenic obesity. Resistance training and adequate protein are the treatment, because loaded muscle is the tissue that keeps its claim on amino acids during an energy deficit; body composition monitoring is how anyone knows whether they worked.

State the evidence tier plainly: this is consensus and observational data, not a randomized trial of GLIM-guided optimization. Trials isolate one disease and exclude the inflamed, multimorbid patient with obesity, so that patient will not be handed to you as a trial result. Measure the mechanism in the patient in front of you. The patient-facing version of the preoperative window is nutrition before surgery and what to measure.

Who to screen and what a finding changes

• Adults with obesity scheduled for elective joint, spine or abdominal surgery, screened alongside the glycemia work in preoperative diabetes screening before surgery.
• Patients about to start incretin therapy, with a repeat once weight loss is established.
• Older adults with an overweight or obese BMI who have slowed down, fallen or report new fatigue, whatever a short-form screen said.
• Patients with persistently elevated CRP or a long history of restrictive dieting and regain.

Write those triggers into your selection criteria and standing orders so the screen does not depend on whether a patient looks thin.

Measura [Cardiometabolic and Autonomic Health Analysis] supplies the objective half of the workup; it does not diagnose or treat malnutrition. Bioimpedance body composition reports skeletal muscle mass, fat mass and segmental distribution, the body-composition step the sarcopenic obesity algorithm calls for after muscle function is tested in your office. Laboratory panels can place high-sensitivity CRP, ferritin, B12, zinc and red blood cell magnesium beside fasting insulin; vitamin D, folate and albumin come from blood work you order. Indirect calorimetry measures resting energy expenditure, which is interpretable only against the lean mass figure from the same visit and gives a protein and energy plan a measured denominator.

A finding changes management in three ways. A GLIM diagnosis built on low muscle mass documents malnutrition in a chart that says obesity, which moves nutritional optimization ahead of the operating date. A lean-mass baseline before incretin therapy turns muscle preservation from advice into an endpoint with a retest date. And sarcopenic obesity in an older adult belongs in the fall-risk work already structured at the annual wellness visit, next to cognitive assessment and fall prevention. Unmeasured is unmanaged. The patient-facing version, for someone told they cannot be malnourished at their weight, is can you be overweight and malnourished.

Frequently asked questions

References

• Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., et al. (2019). GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition, 38(1), 1-9. https://doi.org/10.1016/j.clnu.2018.08.002
• Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Pisprasert, V., et al. (2025). The GLIM consensus approach to diagnosis of malnutrition: A 5-year update. Clinical Nutrition, 49, 11-20. https://doi.org/10.1016/j.clnu.2025.03.018
• Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., et al. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41(4), 990-1000. https://doi.org/10.1016/j.clnu.2021.11.014
• Kayhan Kocak, F. O., Altın, Z., & Kızıltaş, A. (2026). Malnutrition by GLIM and its overlap with sarcopenic obesity in older adults with elevated body mass index: A retrospective cross-sectional study. Nutrition in Clinical Practice, 41(3), 799-810. https://doi.org/10.1002/ncp.70086
• Vieira, F. T., Godziuk, K., Barazzoni, R., Batsis, J. A., Cederholm, T., Donini, L. M., et al. (2025). Hidden malnutrition in obesity and knee osteoarthritis: Assessment, overlap with sarcopenic obesity and health outcomes. Clinical Nutrition, 48, 111-120. https://doi.org/10.1016/j.clnu.2025.03.019
• Pellegrini, M., Rahimi, F., Boschetti, S., Devecchi, A., De Francesco, A., Mancino, M. V., et al. (2021). Pre-operative micronutrient deficiencies in patients with severe obesity candidates for bariatric surgery. Journal of Endocrinological Investigation, 44(7), 1413-1423. https://doi.org/10.1007/s40618-020-01439-7
• Roach, C. S., Wertheimer, B., Shah, K. H., Lu, V. M., Shah, A. H., & Komotar, R. J. (2026). Sarcopenic obesity and cachexia as nutritional risk phenotypes and histology-specific outcomes after intracranial tumor resection: a histology-stratified NSQIP analysis of 27,057 cases. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04450-3
• Chou, W. K., Guidozzi, N., Giorgi, L., Salem, R., & Markar, S. R. (2026). Impact of sarcopenic obesity on outcomes following major abdominal cancer surgery: A population-based observational study. European Journal of Surgical Oncology, 52(4), 111505. https://doi.org/10.1016/j.ejso.2026.111505
• Eisa, N., & Barood, O. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity & Metabolism, 28(6), 4818-4827. https://doi.org/10.1111/dom.70666

Related reading

• Can You Be Overweight and Malnourished? What Your Numbers Show
• Preoperative Diabetes Screening Before Pain Procedures and Surgery
• Bioimpedance Body Composition

Remitted Depression and Cognitive Decline: A Screening Trigger

Remitted depression is a screening trigger for cognitive decline: in one cohort of older adults whose depression had lifted, about one in four developed dementia within five years. That history is a reason to set a standardized cognitive baseline and follow it.

Remission ends the mood episode, not the cognitive risk. A randomized trial built to slow decline in this group shows why the history belongs on the screening list.

Remitted depression and cognitive decline travel together in older adults, and most charts stop tracking cognition the day the mood improves. The PACt-MD trial in Toronto showed that a combined prefrontal intervention could slow cognitive decline in exactly this group, with the clearest effect in patients whose depression was in remission. Measura [Cardiometabolic and Autonomic Health Analysis] provides neither the brain stimulation nor the cognitive remediation used in the trial. The primary care lesson sits upstream of both: a history of late-life depression is a reason to establish a standardized cognitive assessment baseline and follow it.

The risk that persists after remission

A 2025 umbrella review and meta-analysis pooled 18 studies of depression with onset in later life, covering 901,762 participants and 7,595 incident dementia cases, and found a hazard ratio of 1.95 for all-cause dementia; depression assessed in midlife carried a hazard ratio of 1.56. Heterogeneity was substantial, and the authors note that part of the late-life signal may be early neurodegeneration presenting as mood change. Either reading argues for measurement, the case developed in pairing cognitive screening with the metabolic picture.

Clinical cohorts show what that looks like. In a prospective study of 130 older adults with remitted major depression and 100 normal controls, 98 patients and 55 controls completed 5-year follow-up; among the patients, 28.6% had mild cognitive impairment and 25.5% developed dementia within 5 years, an approximate 3 times higher risk of subsequent cognitive decline. Slower information-processing speed and weaker memory at baseline predicted conversion. In a separate cohort of 185 adults with remitted late-life depression and 114 never-depressed controls followed an average of 5 years, the remitted group started with measurable impairment. Those whose first episode came at 60 or later performed worse across domains and declined faster in verbal skills and delayed memory. Age at first episode is a triage variable most charts never record. Stress physiology is part of that picture, and its daily timing is covered in how gut bacteria shape the stress rhythm.

What the PACt-MD trial tested

The trial ran at 5 academic hospitals in Toronto. It enrolled older adults with remitted major depression, with or without mild cognitive impairment, aged 65 and older, or mild cognitive impairment without depression, aged 60 and older. Of 486 who consented, 375 received at least one session; mean age was 72.2 years. The active arm combined cognitive remediation, structured computer-based exercises, with transcranial direct current stimulation targeting the prefrontal cortex, 5 days a week for 8 weeks, followed by twice-yearly 5-day boosters and daily at-home remediation. The comparison arm received sham versions of both. Participants were assessed yearly for 3 to 7 years, over a median follow-up of 48.3 months.

What it found, and what it did not

The active treatment slowed decline on the global cognitive composite, with an adjusted z score difference of 0.21 at month 60, and showed effects on executive function and verbal memory. It produced no meaningful acute improvement at month 2 (0.06), and its effect on progression to mild cognitive impairment or dementia was weak and not statistically significant, with a hazard ratio of 0.66. Benefit was larger in participants with remitted depression and in APOE ε4 noncarriers.

Two secondary reports from the trial refine who responds. Among 246 participants with analyzable baseline MRI, cortical thickness moderated the treatment effect on global cognition, executive function and verbal memory. Among 143 participants in the active arm, a stronger stimulation-induced electric field in the left dorsolateral prefrontal cortex was associated with slower decline.

The non-obvious result is the shape of the effect. An intervention that did nothing measurable at two months separated from sham years later. A single post-treatment score would have called it a failure. Prevention in cognition is visible only through standardized, repeated measurement, and the same is true of the decline a practice is trying to catch, which is how serial results are interpreted. The second point is where the benefit concentrated: in noncarriers of the strongest genetic risk variant, which places the modifiable portion in the terrain rather than the genotype. Protocols that demand years of sessions also favor patients well enough to attend them; the depressed older patient with diabetes, chronic pain and a long medication list is the one primary care actually holds, and the one who most needs measuring. The other changeable risks this patient carries are organized by visit in measuring modifiable dementia risk factors.

Why depression and cognition share a terrain

Two biological drivers link them. The first is prefrontal and executive network dysfunction, the circuit the trial targeted, which impairs processing speed and planning long after mood recovers. The second is systemic: an inflamed subgroup of depressed patients carries elevated inflammatory markers and insulin resistance, the same metaflammation that injures cerebral small vessels and impairs neuronal fuel supply. The third driver is social. Late-life depression clusters with bereavement, retirement, isolation and loneliness, each of which removes daily cognitive and social load. Treatment accordingly includes behavior with a physiological rationale: aerobic and resistance exercise improve insulin sensitivity and cerebral blood flow, and sustained social contact keeps the executive networks under demand. Insulin signaling inside the brain is one of those shared routes, traced in what brain tissue shows about insulin resistance.

Who to screen and what to measure

• Adults 65 and older with a documented history of major depression now in remission.
• Any patient whose first depressive episode began at 60 or later.
• Remitted depression with subjective memory or processing-speed complaints.
• Remitted depression with central adiposity, insulin resistance or vascular risk factors.

A cognitive assessment administered the same way each time provides the baseline and the serial comparison. Laboratory panels address reversible contributors to a low score, including vitamin B12 and a full thyroid panel, and the metabolic drivers, including fasting insulin and high-sensitivity C-reactive protein. Candidates for cognitive remediation or brain stimulation are referred to geriatric psychiatry or research programs; Measura’s role ends at identification and measurement.

The annual wellness visit already screens for depression and reviews cognition, which makes it the natural place to flag a remitted history. Standing orders can start the cognitive and laboratory measurements when that flag is present, and selection criteria keep the trigger consistent across clinicians. Where gait or balance is also a concern, cognitive assessment and fall prevention describes the pairing.

Frequently asked questions

References

• Rajji, T. K., Bowie, C. R., Herrmann, N., Pollock, B. G., Lanctôt, K. L., Kumar, S., et al., & PACt-MD Study Group. (2025). Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry, 82(1), 12-21. https://doi.org/10.1001/jamapsychiatry.2024.3241
• Brain, J., Alshahrani, M., Kafadar, A. H., Tang, E. Y., Burton, E., Greene, L., et al., & Stephan, B. C. (2025). Temporal dynamics in the association between depression and dementia: an umbrella review and meta-analysis. eClinicalMedicine, 84, 103266. https://doi.org/10.1016/j.eclinm.2025.103266
• Lin, Y. J., Huang, M. F., Yeh, Y. C., & Chen, C. S. (2024). Predicting risk of dementia among the elderly with major depressive disorder in remission: A prospective study. International Journal of Geriatric Psychiatry, 39(2), e6065. https://doi.org/10.1002/gps.6065
• Ly, M., Karim, H. T., Becker, J. T., Lopez, O. L., Anderson, S. J., Aizenstein, H. J., et al., & Butters, M. A. (2021). Late-life depression and increased risk of dementia: a longitudinal cohort study. Translational Psychiatry, 11(1), 147. https://doi.org/10.1038/s41398-021-01269-y
• Ho, N. C. W., Zhukovsky, P., Rajji, T. K., Bowie, C. R., Brooks, H., Butters, M. A., et al., & PACt-MD Study Group. (2026). Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment. The American Journal of Geriatric Psychiatry, 34(8), 1005-1015. https://doi.org/10.1016/j.jagp.2026.04.008
• Mirjalili, M., Brooks, H., Ma, C., Lee, A., Bikson, M., Voineskos, A. N., et al., & PACt-MD Study Group. (2025). Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2025.09.020

Related reading

• Inflammation and Depression: Identifying the Inflamed Subgroup
• Cognitive Screening in Primary Care: Add the Metabolic Picture
• Cognitive Assessment

Body Fat Distribution and Dementia Risk: Screening Beyond the Scale

Body fat distribution shifts dementia risk: among 412,691 UK Biobank adults, a central fat pattern and fat concentrated in the arms each predicted more neurodegenerative disease, and muscle strength predicted less.

Where fat sits and how much muscle surrounds it predicted neurodegenerative disease in a very large cohort. Weight and body mass index could not have shown either pattern.

Body fat distribution and dementia risk are linked more tightly than body mass index can show, and the scale in the hallway is built to miss it. In the UK Biobank, a central obesity pattern and a pattern of fat concentrated in the arms each predicted more neurodegenerative disease, muscle strength predicted less, and cardiovascular disease carried up to a third of those associations. For a practice already screening vascular and metabolic risk, the finding moves body composition from a weight-loss metric to a neurological risk marker. Measura [Cardiometabolic and Autonomic Health Analysis] measures the compartments involved with segmental body composition testing; interpretation stays with the treating physician.

What the UK Biobank analysis actually measured

Xu and colleagues analyzed 412,691 UK Biobank participants, mean age 56.0 years and 55.1% female, with no neurodegenerative disease at recruitment. Over an average follow-up of 9.1 years, 8,224 developed a neurodegenerative disease, including Alzheimer and Parkinson disease. To limit reverse causation from the weight loss that precedes diagnosis, follow-up began after a 5-year lag.

The exposure is the detail worth noticing. Whole-body fat and muscle mass, and the same compartments in the arms, legs and trunk, were measured by segmental bioimpedance, alongside grip strength by hand dynamometer and heel bone density by ultrasound. Principal component analysis reduced those measures to patterns rather than single variables. None of the patterns can be reconstructed from height and weight, the same limit set out in screening visceral adiposity beyond BMI. A simpler bedside proxy for the same central pattern is a waist index adjusted for weight in hypertensive patients.

The patterns that raised and lowered risk

Patterns labeled central obesity and arm-dominant fat distribution were associated with a higher rate of neurodegenerative disease, with hazard ratios of 1.13 to 1.18. Patterns for muscle strength, bone density and leg-dominant fat distribution, among others, were associated with a lower rate, with hazard ratios ranging from 0.74 to 0.94. Among single components, high versus low grip strength carried a hazard ratio of 0.73. Estimates were comparable across polygenic risk, APOE genotype and family history strata, so the association is not confined to the genetically susceptible.

In a subcohort of 40,790 participants with brain MRI, the central obesity, arm-dominant fat and muscle strength patterns tracked brain atrophy and cerebral small vessel disease in the same directions, which argues against a diagnosis-coding artifact and for recording a cognitive assessment beside the composition result. Composition is one of several changeable risks that can be charted, sorted in which dementia risk factors a visit can measure.

The cardiovascular route, and the part it does not explain

Mediation analysis attributed 35.3% of the central obesity association, 14.3% of the arm-dominant fat association and 10.7% of the muscle strength association to incident cardiovascular disease, with cerebrovascular disease the largest contributor at 8.9% to 28.9% across patterns. Roughly two-thirds of the central obesity signal therefore runs through something other than a diagnosed vascular event.

The authors point to ectopic fat, impaired insulin signaling and proinflammatory cytokines. That is the two-driver picture in practice: vascular injury on one side, and on the other the insulin resistance and metaflammation from ectopic fat described in insulin resistance and dementia screening. A 2026 imaging study of cognitively normal midlife adults, average age 49.8 years, adds the brain end of the chain, with visceral fat correlating with amyloid PET burden (rho 0.36) in women and White participants and a higher visceral-to-subcutaneous ratio associated with cortical tau. That imaging is done elsewhere, but the depot it describes is the one body composition estimates. The third driver is behavioral and structural: sedentary work, a food supply built on acellular carbohydrate, and a visit that records weight because weight is what the scale in the hallway produces.

Newer UK Biobank work: hips, metabolic treatment and muscle

Three later UK Biobank studies sharpen the clinical reading. In 440,861 UK Biobank participants followed a median 12.7 years, waist circumference was positively associated with dementia, predominantly vascular dementia, but the association disappeared after adjustment for treatments for metabolic disorders, while larger hip circumference was protective, with a highest-versus-lowest quartile hazard ratio of 0.75 in women and 0.83 in men. The harm of central fat appears to travel through a metabolic state that is treatable, and the gluteofemoral depot behaves differently from the abdominal one.

In 152,028 participants followed a median 14.1 years, carrying all three components of osteosarcopenic adiposity, low bone density, low muscle mass or grip strength and high body fat percentage, raised the hazard of Alzheimer-related dementia to 1.46, and optimal cardiovascular health attenuated that risk. In 190,406 participants, each 5-kg lower grip strength was associated with incident dementia at a hazard ratio of 1.20 in men and 1.12 in women.

A 2026 meta-analysis of cohort studies resolves an apparent paradox. Late-life obesity looked protective against dementia (hazard ratio 0.83), while sarcopenia raised risk (hazard ratio 1.42). Weight in late life is confounded by the muscle and weight loss that precede diagnosis; composition separates what weight blends together, and balance testing catches the fall risk that muscle loss brings. Low muscle hidden under excess weight is its own screening problem, set out in malnutrition in patients with obesity.

Who to measure, and what a finding changes

Weight-based screening misclassifies two patients this literature cares about: the older adult whose stable weight hides muscle loss, and the normal-BMI South Asian or East Asian patient who is thin outside and fat inside, metabolically inflamed and insulin resistant at a body mass index that looks reassuring. Written selection criteria should name both.

• Central or arm-dominant adiposity on segmental bioimpedance body composition. Treat it as a neurovascular risk marker: add arterial stiffness and endothelial function for the cardiovascular mediator and laboratory panels with fasting insulin and lipids for the metabolic one.
• Low muscle mass relative to fat. Pair a cognitive assessment baseline with vestibular and balance testing, because the same patient carries fall risk. Resistance training is treatment here, not advice: skeletal muscle is the largest site of insulin-mediated glucose disposal, so adding muscle improves the insulin signaling the mediation analysis could not account for.
• Serial measurement. Patterns change slowly and measurement conditions move bioimpedance, so repeat under the same fasting and hydration conditions and read the trend, as outlined in interpreting the report.

The limits belong in one sentence: these are observational cohorts of healthier-than-average volunteers with the patterns derived inside them, so a Measura result informs risk and follow-up rather than assigning a hazard ratio to an individual. The metabolically complicated patient is underrepresented in such cohorts, which is an argument for measuring that patient, not for waiting. Pairing the findings with cognition is set out in cognitive assessment and fall prevention.

Frequently asked questions

References

• Xu, S., Wen, S., Yang, Y., He, J., Yang, H., Qu, Y., Zeng, Y., Zhu, J., Fang, F., & Song, H. (2024). Association Between Body Composition Patterns, Cardiovascular Disease, and Risk of Neurodegenerative Disease in the UK Biobank. Neurology, 103(4), e209659. https://doi.org/10.1212/WNL.0000000000209659
• Liu, Z. Y., Qian, Y. W., Gu, J. M., Shao, X. P., Miao, M. Y., Lyu, J. Q., et al., & Chen, G. C. (2025). Association of Android and Gynoid Fatness With Incident Dementia and Brain Structure. Journal of Cachexia, Sarcopenia and Muscle, 16(5), e70095. https://doi.org/10.1002/jcsm.70095
• Wang, W., Ren, R., Yang, H., Jiang, J., Ye, X., Wang, C., et al., & Wang, D. (2025). Healthy Cardiovascular Status Attenuates the Detrimental Association Between Osteosarcopenic Adiposity and Alzheimer’s Disease-Related Dementia: A UK Biobank Cohort Study. Journal of the American Heart Association, 14(11), e041697. https://doi.org/10.1161/JAHA.125.041697
• Duchowny, K. A., Ackley, S. F., Brenowitz, W. D., Wang, J., Zimmerman, S. C., Caunca, M. R., & Glymour, M. M. (2022). Associations Between Handgrip Strength and Dementia Risk, Cognition, and Neuroimaging Outcomes in the UK Biobank Cohort Study. JAMA Network Open, 5(6), e2218314. https://doi.org/10.1001/jamanetworkopen.2022.18314
• Booranasuksakul, U., Guan, Z., Radin Pereira, L., Tsintzas, K., Macdonald, I., Stirling, E., et al., & Siervo, M. (2026). Sarcopenia, obesity, sarcopenic obesity and dementia risk: a systematic review and meta-analysis of cohort studies. International Journal of Food Sciences and Nutrition, 1-16. https://doi.org/10.1080/09637486.2026.2722926
• Dolatshahi, M., Commean, P. K., Naghashzadeh, M., Kassani, S. H., Rahmani, F., Xu, Y., et al., & Raji, C. A. (2026). Abdominal adiposity and Alzheimer’s disease imaging markers across sex and race at midlife. Journal of Alzheimer’s Disease, 112(2), 991-1003. https://doi.org/10.1177/13872877261455657

Related reading

• Visceral Adiposity: Screening for the Risk That BMI Misclassifies
• Insulin Resistance and Dementia: Screening Past the Glucose
• Bioimpedance Body Composition

Modifiable Risk Factors for Dementia: What Primary Care Can Measure

Primary care can measure four of the 14 modifiable dementia risk factors in the 2024 Lancet Commission with a number: blood pressure, glucose regulation, LDL cholesterol and adiposity. The others have to be asked about, and some were settled long before the visit.

A population estimate of preventable dementia does not tell a clinician what to order. Sorting the risk factors by how they reach the chart does.

Modifiable risk factors for dementia now number 14 in the 2024 Lancet Commission, which estimates that 45% of dementias worldwide are preventable if all 14 were eliminated. The standard visit measures perhaps four of them with a blood pressure cuff, a glucose and a lipid panel, and files the rest as yes-or-no history. That gap, not the list, is the primary care problem: which factors can be measured, which have to be asked about, and which were settled long before the patient reached the exam room. Measura [Cardiometabolic and Autonomic Health Analysis] addresses the measurable portion, from a standardized cognitive assessment baseline to the metabolic and vascular numbers behind it, and it helps to be exact about where that portion ends.

The 14 factors, sorted by how they reach the chart

The Commission’s list runs across the life course: less education early in life; hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity and excessive alcohol use in midlife; and social isolation, air pollution and vision loss in late life. High LDL cholesterol and untreated vision loss were the additions in the 2024 report. For a clinic workflow they fall into three groups.

• Measured with a number. Blood pressure, glucose regulation, LDL cholesterol and adiposity. This is where measurement can go past the default: fasting insulin beside glucose and hemoglobin A1c on laboratory panels, fat and muscle compartments on bioimpedance body composition instead of body mass index, and vessel wall behavior on arterial stiffness and endothelial function, which records what years of hypertension and hyperglycemia have done rather than today’s reading.
• Screened with an instrument. Depression, hearing, vision, alcohol use and social isolation. Hearing and vision testing are done by audiology and eye care, not by Measura; validated questionnaires cover the rest.
• Taken as history. Education, head injury and air pollution exposure. They cannot be changed at the visit, but they change how a borderline cognitive score should be read.

What the attributable fractions look like in real cohorts

The global figure pools very different populations, and cohort data narrow it. Norway’s HUNT study collected all 14 factors across adulthood in the same people and made its own dementia diagnoses in adults 70 and older. Among 9,745 participants, the authors concluded that addressing all 14 Lancet risk factors could prevent over half of all dementia cases.

In the United States, the Dementia Risk Prediction Project pooled 37,931 participants across six longitudinal cohorts and split the question by age. Factors present in midlife, 45 to 64, accounted for 22.7% of dementia cases, and factors present in late life, 65 and older, for 16.5%. The largest single contributors were late-life physical inactivity at 10.4%, lower education at 8.1% and midlife obesity at 7.7%. Two of the top three are body and behavior, and one of them is measured poorly by weight.

The vascular timeline is sharper. In the Atherosclerosis Risk in Communities study, with 33 years of follow-up in Black and White adults from four US communities, the share of dementia by age 80 attributable to at least one of hypertension, diabetes or current smoking was 21.8% when those factors were measured at 45 to 54 and 44.0% when they were measured at 65 to 74. After 80, only 2% to 8% of cases were attributable to them. The decade of the annual wellness visit is the decade in which measured vascular risk carries the most attributable dementia, and the window narrows quickly after it.

One factor hides behind a normal eye chart. In a cross-sectional analysis of 2,767 older adults in the National Health and Aging Trends Study, a nationally representative sample of US Medicare beneficiaries, 19.0% of prevalent dementia was attributable to at least one objectively measured vision impairment, and contrast sensitivity impairment carried the largest share at 15.0%. A distance acuity chart does not test contrast sensitivity, so the patient who reads the bottom line can still carry the vision deficit most closely tied to dementia. Depression carries its own attributable share, and why remission does not close it is covered in remitted depression as a screening trigger.

Why the measurable factors cluster in one patient

Hypertension, diabetes, obesity, high LDL cholesterol and inactivity are usually charted as five problems. Biologically they converge on two. The first is insulin resistance, which starves insulin-dependent neurons of fuel and feeds the metaflammation that stiffens vessels. The second is the cerebral microvasculature itself, where a stiffened aorta delivers pulsatile pressure into small vessels built for steady flow. The third driver is social and economic: less schooling, food environments dominated by acellular carbohydrate and industrial seed oils, and isolation cluster in the same neighborhoods and the same patients. Metabolic health is already the exception: fewer than 12.2% of US adults qualified in NHANES 2009 to 2016, and the stricter post-2021 criteria put the share under 7%. Trials that test one factor at a time exclude this patient. The patient in the exam room carries five at once, which is why measuring the shared terrain beats counting diagnoses.

A less obvious link sits in the traumatic brain injury item. In older adults, head injury is most often a fall, and falls follow balance, vision, orthostatic blood pressure and cognition together. Vestibular and balance testing therefore belongs in dementia prevention as much as in fall prevention. Where fat and muscle sit adds a further measurable layer, discussed in body composition patterns and neurodegenerative risk.

Does changing the factors change cognition?

The largest US test is the POINTER trial, which enrolled 2,111 adults aged 60 to 79 with a sedentary lifestyle and suboptimal diet plus other risk criteria at 5 US clinical sites. Both a structured and a self-guided lifestyle program raised global cognition over two years, and the structured program did so faster by 0.029 SD per year, with benefit in APOE ε4 carriers and noncarriers alike. The effect is modest, and a 2025 review argues that individual-level programs work within limits set by social and commercial determinants. The practice position is that lifestyle and behavior are treatment: exercise improves insulin sensitivity and cerebral blood flow, and structure, accountability and repeated measurement are what distinguished the stronger arm.

Detection before symptoms is moving toward physiology

Research is also pushing detection earlier. In 137 community-dwelling Black Americans aged 60 to 90 recruited through Wayne State University and the Michigan Alzheimer’s Disease Research Center, 84 cognitively healthy and 53 with mild cognitive impairment, a resting-state EEG connectivity model separated the groups with 91.97% leave-one-out cross-validation accuracy and predicted progression trends over 9 to 18 months with 84.61% accuracy in a limited subset. Measura does not perform EEG; that work remains in research settings. What a practice can do now is fix a standardized cognitive assessment as a baseline and repeat it under the same conditions. Before a slipping score is labeled dementia, a reversible liver cause is worth excluding, as described in liver fibrosis screening in patients with dementia.

Workflow: turning the list into orders

Most of the 14 already have a home in the annual wellness visit, which asks about depression, function and cognition. The gap is conversion of the measurable factors into measurements rather than yes-or-no history. Standing orders let staff start the metabolic, vascular and body composition measurements when a trigger is documented, and cognitive assessment and fall prevention describes pairing the cognitive baseline with balance findings. Documenting each factor as measured, screened or historical makes the risk profile legible to the next clinician.

Frequently asked questions

References

• Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., et al., & Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572-628. https://doi.org/10.1016/S0140-6736(24)01296-0
• Ma’u, E., Cullum, S., Röhr, S., & Brayne, E. C. (2025). Are modifiable risk factors for dementia really modifiable? Current Opinion in Psychiatry, 38(5), 348-354. https://doi.org/10.1097/YCO.0000000000001018
• Ellingjord-Dale, M., Strand, B. H., Skirbekk, V., Bratsberg, B., Mekonnen, T., Zotcheva, E., et al., & Engdahl, B. (2025). Potentially modifiable risk factors for dementia in Norway (HUNT4 70+): a retrospective cohort study. The Lancet Healthy Longevity, 6(12), 100802. https://doi.org/10.1016/j.lanhl.2025.100802
• Li, J. M., Gauen, A. M., Zmora, R., Stephen, J. J., Petito, L. C., Scholtens, D., et al., & Allen, N. B. (2026). Midlife and late-life population attributable fractions of risk factors for dementia in the United States: The Dementia Risk Prediction Project. Alzheimer’s & Dementia, 22(1), e71065. https://doi.org/10.1002/alz.71065
• Smith, J. R., Pike, J. R., Gottesman, R. F., Knopman, D. S., Lutsey, P. L., Palta, P., et al., & Deal, J. A. (2025). Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia. JAMA Neurology, 82(7), 644-654. https://doi.org/10.1001/jamaneurol.2025.1495
• Smith, J. R., Huang, A. R., Zhou, Y., Varadaraj, V., Swenor, B. K., Whitson, H. E., et al., & Ehrlich, J. R. (2024). Vision Impairment and the Population Attributable Fraction of Dementia in Older Adults. JAMA Ophthalmology, 142(10), 900-908. https://doi.org/10.1001/jamaophthalmol.2024.3131
• Baker, L. D., Espeland, M. A., Whitmer, R. A., Snyder, H. M., Leng, X., Lovato, L., et al., & Carrillo, M. C. (2025). Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA, 334(8), 681-691. https://doi.org/10.1001/jama.2025.12923
• Deng, J., Sun, B., Kavcic, V., Liu, M., Giordani, B., & Li, T. (2024). Novel methodology for detection and prediction of mild cognitive impairment using resting-state EEG. Alzheimer’s & Dementia, 20(1), 145-158. https://doi.org/10.1002/alz.13411

Related reading

• Dementia Prevention Starts With Numbers You Can Measure Now
• Cognitive Screening in Primary Care: Add the Metabolic Picture
• Laboratory Panels

Metabolic Osteoarthritis: Screening the Hand and Younger Joint

Metabolic osteoarthritis screening belongs in two presentations: osteoarthritis in the finger joints, which carry almost no load, and osteoarthritis that starts unexpectedly young. In both, a glycemic, insulin and lipid panel is the right first test.

Load explains the knee. It does not explain the interphalangeal joint, and it does not explain a fifty-year-old with four affected sites. Those two presentations are the screening trigger.

Metabolic screening in osteoarthritis is usually skipped for a reason that sounds like physiology: the joint hurts because it carries weight. That reasoning holds at the knee and collapses in the hand. The distal and proximal interphalangeal joints carry essentially nothing, and they are where the systemic signal separates most cleanly from the load signal. So does age at onset. Those two presentations, the inflamed hand and the unexpectedly young joint, are where a referral for a brace and an analgesic is answering the wrong question, and a glycemic, insulin and lipid panel is the right first one.

What the adjusted data support, and what they do not

Be precise, because this literature is overstated in both directions. Diabetes and osteoarthritis travel together: a meta-analysis of 49 studies put the odds of osteoarthritis in diabetes at 1.46, with an average osteoarthritis prevalence of 29.5% among 5788 patients with diabetes. Of the 12 included studies that adjusted for body mass index, 7 kept diabetes as an independent risk factor and 5 did not. That split is the honest state of the field.

Adiposity carries the strongest causal signal. In a Swedish general-population cohort of 10,633 adults with no osteoarthritis diagnosis and no joint pain at baseline, metabolic syndrome carried a hazard of 1.17 for incident osteoarthritis in any joint. Elevated waist circumference alone carried 1.42, and metabolic syndrome without an elevated waist carried 1.02, which is nothing. Across 271,019 participants from the UK Biobank and the National Health and Nutrition Examination Survey, with Mendelian randomization alongside, metabolic syndrome was not an independent risk factor once body mass index was accounted for, risk began climbing around a body mass index of 27, and waist circumference was the component that mattered, the argument behind screening visceral adiposity beyond BMI.

The loading model is not wrong; it is incomplete, and the genetics say so. A cross-trait analysis found a genetic correlation between metabolic syndrome and osteoarthritis of 0.393, with Mendelian randomization supporting liability to metabolic syndrome raising osteoarthritis risk and no reverse effect. Staging the whole cardiometabolic picture sharpens it further. Among 256,364 UK Biobank participants without osteoarthritis at baseline, the most advanced cardiovascular-kidney-metabolic stage carried hazards of 1.76 for hip and 2.67 for knee osteoarthritis against stage 0, and the associations were stronger in younger participants.

The hand is the phenotype that survives adjustment

This is the finding that should change a referral note. In 952 women aged 45 to 65 from the Chingford cohort, metabolic syndrome was associated with painful knee osteoarthritis until body mass index entered the model, at which point it vanished. The association with painful interphalangeal osteoarthritis survived adjustment for both age and body mass index, and four of the five syndrome components tracked with it. Weight itself is associated with hand osteoarthritis: a systematic review of 25 studies graded the evidence moderate with an approximate risk ratio of 1.9, which load cannot explain in a joint that bears no body weight; the same logic already makes carpal tunnel a diabetes screening trigger. In a dedicated hand osteoarthritis cohort, metabolic syndrome went with more pain independent of structural damage and of anxiety and depression scores.

Two biological drivers account for that. Adipose tissue is an endocrine organ, and the metaflammation it generates, adipokines and cytokines, reaches cartilage in the finger as readily as cartilage in the knee. Hyperglycemia acts on the tissue itself, through glycation and oxidative stress in a matrix that turns over slowly. The third driver is structural: osteoarthritis is coded, referred and treated as a mechanical diagnosis, so the patient goes to physical therapy or an injector and nobody is assigned the terrain. Dr. Padda admits to years of closing visits by telling patients with a borderline A1c that the number could wait. A hand radiograph in that patient is a second chance to stop saying it. Periodontal inflammation is another tissue signal that runs ahead of a metabolic diagnosis, set out in sugar, gum inflammation and what to measure.

What a finding changes in management

Three things, and none is a new drug.

First, the weight conversation becomes a measured intervention with a comparator rather than a handout. In a 68-week randomized trial of 407 adults with obesity and moderate knee osteoarthritis, once-weekly semaglutide produced a mean weight change of -13.7% against -3.2% on placebo, with pain scores falling -41.7 points against -27.5. That is what treating adiposity as the driver can do.

Second, body composition changes the target. A meta-analysis of 12 studies found low muscle mass index associated with knee osteoarthritis at 1.36 and sarcopenic obesity at 1.78, on low-quality evidence. A patient who loses weight and keeps losing muscle has not improved, and only measured body composition shows it. Loading and protein intake are treatment, each with its physiological rationale documented.

Third, fall risk enters the plan. Across 17 studies and 862,849 participants, symptomatic knee osteoarthritis carried 1.55 times the odds of recurrent falls. In an older patient with knee pain, sarcopenic obesity and unsteadiness, the joint diagnosis and the fall risk are one problem.

None of this argues against the injection. A joint injection is the bridge: it controls pain now so the patient can load the joint, sleep and do the metabolic work. The failure mode is a bridge with nothing on the other side, and the metabolic panel is how the other side gets built. Patients who ache in several joints at once often carry the visceral pattern described in the MRI evidence linking belly fat to chronic pain.

Who to test

• Any patient with hand osteoarthritis, particularly interphalangeal involvement with pain out of proportion to radiographic grade.
• Osteoarthritis at an age or in a joint distribution that load does not explain, including multi-joint disease before the sixth decade.
• Patients whose waist circumference is above target regardless of body mass index category.
• Patients with diabetes or an A1c in the prediabetic band being referred for injection, physical therapy or arthroplasty evaluation.
• Older patients with knee or hip osteoarthritis who report unsteadiness, a near-fall or a fall.
• Patients told to lose weight at several visits in a row without any measured change being recorded.

Written selection criteria keep that list consistent across clinicians. For patients already scheduled for joint replacement, the preoperative window is covered in what to have measured before surgery.

What Measura measures in this pathway

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment; radiographs and joint imaging are done elsewhere, and findings return to the ordering physician. Three measurements apply:

• Laboratory panels for the glycemic and lipid picture, with fasting insulin reported beside glucose and A1c, plus inflammatory markers and lipid particle detail.
• Bioimpedance body composition to separate fat from lean mass, the only practical way to catch sarcopenic obesity before it is advanced.
• Vestibular and balance testing where an older patient with lower-limb osteoarthritis reports unsteadiness, documented with a cognitive baseline through the cognitive assessment and fall prevention workflow.

None of these measures cartilage, and no metabolic result diagnoses or grades osteoarthritis. What they supply is the phenotype the radiograph cannot show.

Building it into the referral

Attach the panel to the diagnosis rather than to the encounter. A standing order that triggers metabolic labs and body composition on a new hand osteoarthritis diagnosis, or on any osteoarthritis diagnosis under sixty, is the version that survives a busy clinic. Recorded at the annual wellness visit, where fall risk and cognition are already structured, the results support the cardiometabolic documentation those visits capture, as documentation rather than as an indication in itself. The same reasoning for tendon disease is in tendinopathy as a metabolic signal, and the pre-procedure version is in metabolic screening before repeat joint injections.

The limits, stated once: almost all of this is observational, most of the metabolic syndrome signal in weight-bearing joints is adiposity rather than the syndrome, and reverse causation is possible where pain limits activity. Trials that could settle causation enroll one disease at a time and screen out the patient with obesity, diabetes, depression and three painful joints, who is the patient actually in the exam room. The hand data and the genetic data keep the systemic reading alive, and the practice position follows from them. Measure the terrain in the patient whose joints cannot be explained by what they carry, then measure it again to see whether it moved.

Frequently asked questions

References

• Louati, K., Vidal, C., Berenbaum, F., & Sellam, J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1(1), e000077. https://doi.org/10.1136/rmdopen-2015-000077
• Yusuf, E., Nelissen, R. G., Ioan-Facsinay, A., Stojanovic-Susulic, V., DeGroot, J., van Osch, G., Middeldorp, S., Huizinga, T. W., & Kloppenburg, M. (2010). Association between weight or body mass index and hand osteoarthritis: a systematic review. Annals of the Rheumatic Diseases, 69(4), 761-765. https://doi.org/10.1136/ard.2008.106930
• Sanchez-Santos, M. T., Judge, A., Gulati, M., Spector, T. D., Hart, D. J., Newton, J. L., Arden, N. K., & Kluzek, S. (2019). Association of metabolic syndrome with knee and hand osteoarthritis: A community-based study of women. Seminars in Arthritis and Rheumatism, 48(5), 791-798. https://doi.org/10.1016/j.semarthrit.2018.07.007
• Charton, A., Lacoste-Badie, R., Tuffet, S., Rousseau, A., Maheu, E., Fautrel, B., Dougados, M., Berenbaum, F., Courties, A., & Sellam, J. (2025). Metabolic syndrome is associated with more pain in hand osteoarthritis: Results from the DIGICOD cohort. Osteoarthritis and Cartilage Open, 7(1), 100573. https://doi.org/10.1016/j.ocarto.2025.100573
• Andrea, D., Karin, M., Johanna, V., Stefan, L. L., Martin, E., & Ali, K. (2026). The role of metabolic syndrome in osteoarthritis development: Is obesity the key driver? Osteoarthritis and Cartilage Open, 8(1), 100739. https://doi.org/10.1016/j.ocarto.2025.100739
• Wang, J., Peng, L., Xu, P., Guo, F., Xu, X., Wang, J., Yu, H., Xu, K., Yang, Z., Guo, J., & Yang, M. (2025). Unraveling the connection between obesity, metabolic syndrome and osteoarthritis risk: a large-observational study. Diabetology & Metabolic Syndrome, 18(1), 27. https://doi.org/10.1186/s13098-025-02059-y
• Huang, J. X., Xu, S. Z., Tian, T., Wang, J., Jiang, L. Q., He, T., Meng, S. Y., Ni, J., & Pan, H. F. (2025). Genetic Links Between Metabolic Syndrome and Osteoarthritis: Insights From Cross-Trait Analysis. The Journal of Clinical Endocrinology and Metabolism, 110(2), e461-e469. https://doi.org/10.1210/clinem/dgae169
• Ma, Z., Zhang, Y., Li, L., Zheng, G., Yang, H., Zhang, R., Li, Y., Wang, W., Ji, C., Xia, Y., & Zhao, Y. (2026). Association of cardiovascular-kidney-metabolic syndrome with risk of hip/knee osteoarthritis: A prospective cohort study. Maturitas, 212, 109056. https://doi.org/10.1016/j.maturitas.2026.109056
• Bliddal, H., Bays, H., Czernichow, S., Udden Hemmingsson, J., Hjelmesaeth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Velez Sanchez, P., Wharton, S., Wizert, A., & Kristensen, L. E. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine, 391(17), 1573-1583. https://doi.org/10.1056/NEJMoa2403664
• Wu, Q., Xu, Z., Ma, X., Li, J., Du, J., Ji, J., Ling, X., Kan, J., & Zhao, M. (2024). Association of low muscle mass index and sarcopenic obesity with knee osteoarthritis: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 21(1), 2352393. https://doi.org/10.1080/15502783.2024.2352393
• Zhang, Y., Li, X., Wang, Y., Ge, L., Pan, F., Winzenberg, T., & Cai, G. (2023). Association of knee and hip osteoarthritis with the risk of falls and fractures: a systematic review and meta-analysis. Arthritis Research & Therapy, 25(1), 184. https://doi.org/10.1186/s13075-023-03179-4

Related reading

• Tendinopathy as a Metabolic Signal: Screening Before the Procedure
• Corticosteroid-Induced Hyperglycemia After Joint Injections
• Laboratory Panels

Screening for Cirrhosis in Dementia: The Encephalopathy in the Chart

Screening for cirrhosis in dementia means computing a FIB-4 index from values already in the chart. In two national cohorts, 5% to 13% of patients with dementia had scores pointing to undiagnosed advanced fibrosis or cirrhosis, and hepatic encephalopathy, unlike most dementia, responds to treatment.

A dementia diagnosis ends most cognitive workups. In a meaningful share of patients, routine laboratory values point to a liver that nobody has examined.

Screening for cirrhosis in dementia is not routine, and two national cohorts show it has to be. Hepatic encephalopathy produces confusion, slowed thinking, sleep reversal and personality change, the same features that earn an older adult a dementia label, and unlike most dementia it responds to treatment. When cirrhosis has never been diagnosed, nobody asks, and a scored cognitive assessment gets read as proof of decline rather than a baseline that could improve. A FIB-4 index computed from values already in the chart asks the question, and a positive answer reopens a workup the diagnosis had quietly closed.

What the veteran and TriNetX cohorts found

Bajaj and colleagues examined Veterans Health Administration records from 2009 to 2019 for 177,422 US veterans with a dementia diagnosis at two or more visits, no prior cirrhosis diagnosis and enough laboratory data to calculate FIB-4. The cohort was 97.1% men with a mean age of 78.35 years, and FIB-4 was capped at age 65 in the calculation.

• 5.3% (9,373) had FIB-4 above 3.25, the threshold suggestive of cirrhosis.
• 10.3% (18,390) had FIB-4 above 2.67, suggestive of advanced fibrosis.
• A local validation cohort of patients with dementia showed high FIB-4 in 4.4% to 11.2%.
• FIB-4 above 3.25 was associated with viral hepatitis (odds ratio 1.79) and congestive heart failure (1.48), and inversely associated with diabetes (0.78).

Veterans are overwhelmingly male, so the group repeated the analysis in the multi-center TriNetX network: 68,807 patients with dementia and no cirrhosis diagnosis, 44.7% male, mean age 72.73 years. FIB-4 exceeded 3.25 in 7.6% (5,815) and 2.67 in 12.8% (8,683). Congestive heart failure (odds ratio 1.73) again rose with high scores and diabetes (0.82) again ran inverse. The authors concluded that FIB-4 could be used to screen for potential undiagnosed cirrhosis in patients with dementia. Across both cohorts, somewhere between one in twenty and one in eight patients carrying a dementia diagnosis had a laboratory signature demanding a liver workup that nobody had ordered. The case for liver screening despite normal enzymes is in MASLD screening in primary care.

Reading FIB-4 in the oldest patients

Age is a multiplier in the formula, so the index behaves differently in a memory clinic than in the populations that validated it. In a biopsy cohort from European specialist hepatology clinics, specificity of FIB-4 for advanced fibrosis fell with age and was 35% in those aged 65 and older (n=76). A cut-off of 2.0 in that age group restored specificity to 70% with a sensitivity of 77%. That is why the veteran analysis capped age at 65 years even for those above this cutoff. An uncapped calculator run across a dementia panel overcalls, and overcalling is how a useful screen gets abandoned.

Three confounders belong in the note. Congestive hepatopathy raises FIB-4 through the liver, and both cohorts found heart failure among its strongest associations, so a high value in heart failure is a reason to look at both organs, not to dismiss either. Platelet counts fall for reasons other than portal hypertension, including marrow disease and medication, so read them against the full laboratory panel. And the inverse association with diabetes runs against the metabolic expectation; a retrospective design cannot explain it, and it is no reason to skip patients with diabetes, whose fatty liver is the commonest road to cirrhosis in a metabolic practice. A plain-language version for patients holding their own score is what a fatty liver fibrosis score means.

Why covert encephalopathy goes unrecognized

Covert hepatic encephalopathy has no asterixis and no overt confusion. It lives in attention, processing speed and executive function, the exact domains that dementia screening reads as decline. At 16 medical centers across China, 528 patients with cirrhosis underwent psychometric and Stroop testing, and the prevalence of covert encephalopathy was 50.4%. Among cirrhotic patients referred to a dedicated clinic for cognitive complaints and given a full neuropsychological, EEG and MRI workup, about two thirds had covert encephalopathy; 73% of those also had another cause of impairment, most often cerebrovascular or psychiatric, and clinical improvement was observed in 77% of the patients re-evaluated after specific management. A second diagnosis does not cancel the treatable one.

Liver disease short of cirrhosis already shows up on cognitive testing. In 69 outpatients with fatty liver disease, mean age 50.4 years, 32% scored below a Montreal Cognitive Assessment of 26 and 12% had encephalopathy detected on the EncephalApp test. Genetic evidence points the same way: in a two-sample Mendelian randomization analysis, genetically predicted liver fibrosis and cirrhosis carried an odds ratio of 1.849 for vascular dementia.

The cascade runs through three drivers. First, gut-derived ammonia and bacterial products reach the brain once a scarred liver and portosystemic shunting stop filtering them; the first brain, the gut, becomes the source of the second brain’s toxin load. Second, skeletal muscle is the backup clearance route for ammonia, so sarcopenic wasting in an older patient removes the reserve at the moment the liver fails, which is why measured muscle mass belongs in this workup. Third, and most preventable, is the system: once a chart says dementia, every later cognitive change is pre-explained, alcohol use and isolation in older adults go unasked, and the liver panel is filed instead of calculated. The diagnosis becomes the reason nobody looks.

What a positive screen changes

A high FIB-4 in a patient with dementia is a referral trigger, not a diagnosis. Confirming fibrosis with elastography, staging cirrhosis and diagnosing encephalopathy belong to hepatology and imaging services. What changes in primary care is the frame, because hepatic encephalopathy is treatable. At 11 teaching hospitals in China, 98 cirrhotic patients with minimal encephalopathy were randomized to lactulose or no therapy, and at day 60 the reversal rate was 64.18% with lactulose against 22.58% without, a number needed to treat of 2.4. The 2014 joint American and European guideline builds management around correcting precipitants: sedatives, opioids, dehydration, infection and constipation.

A positive screen also demands cognitive testing that is repeated rather than recorded once. If the score improves after encephalopathy treatment, the dementia label was at least partly wrong; if it does not, the patient has lost nothing but an unexamined assumption. Nutrition becomes treatment with a mechanism: adequate protein and muscle loading rebuild the ammonia-clearing capacity the liver has lost. The broader metabolic reading of a slipping cognitive score is in cognitive screening in primary care: add the metabolic picture. Hepatic encephalopathy belongs on the same differential as the changeable dementia risks sorted in turning dementia risk factors into orders.

Where the measurements fit

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It does not diagnose cirrhosis or hepatic encephalopathy, and it does not treat. It supplies the measurements:

• Cognitive assessment establishes a scored baseline that can be repeated after hepatology review or treatment, turning a diagnostic assumption into a measured change.
• Laboratory panels include hepatic panel groups selected to the clinical question; the ordering physician can confirm that AST, ALT and a platelet count are drawn together so FIB-4 can be calculated in the chart.
• Bioimpedance body composition quantifies muscle mass, the second ammonia-clearance organ and a fall risk in its own right.

Building the screen into standing orders

The screen survives only when it is automatic. A rule in standing orders can require FIB-4 calculation, age capped or age-adjusted, whenever a dementia or mild cognitive impairment diagnosis is added and liver chemistry and a platelet count are on file. The annual wellness visit already requires cognitive assessment; recording the FIB-4 result and any referral beside it keeps the finding visible (see annual wellness visit integration), and pairing it with fall screening follows the structure in cognitive assessment and fall prevention. Unmeasured is unmanaged, and a reversible encephalopathy filed as dementia is the most expensive thing never measured.

Frequently asked questions

References

• Bajaj, J. S., Silvey, S. G., Rogal, S., O’Leary, J. G., Patton, H., Morgan, T. R., Kanagalingam, G., Gentili, A., et al. (2024). Undiagnosed cirrhosis and hepatic encephalopathy in a national cohort of veterans with dementia. JAMA Network Open, 7(1), e2353965. https://doi.org/10.1001/jamanetworkopen.2023.53965
• Silvey, S., Sterling, R. K., French, E., Godschalk, M., Gentili, A., Patel, N., & Bajaj, J. S. (2024). A possible reversible cause of cognitive impairment: undiagnosed cirrhosis and potential hepatic encephalopathy in patients with dementia. The American Journal of Medicine, 137(11), 1082-1087.e1. https://doi.org/10.1016/j.amjmed.2024.06.014
• McPherson, S., Hardy, T., Dufour, J. F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., et al. (2017). Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. The American Journal of Gastroenterology, 112(5), 740-751. https://doi.org/10.1038/ajg.2016.453
• Zeng, X., Yin, C., Sun, C. Y., Lu, C. H., Zhao, S. S., Gao, X. H., Chen, D. F., Wen, L. Z., et al. (2023). Prevalence and risk factors of covert hepatic encephalopathy in cirrhotic patients: a multicenter study in China. Journal of Digestive Diseases, 24(2), 122-132. https://doi.org/10.1111/1751-2980.13171
• Sultanik, P., Kheloufi, L., Leproux, A., Bouzbib, C., Mouri, S., Santiago, A., Galanaud, D., Navarro, V., et al. (2024). Other causes of neurocognitive impairment than covert hepatic encephalopathy (CHE) are very frequent, either alone or associated with CHE, in cirrhotic patients with cognitive complaints. Alimentary Pharmacology & Therapeutics, 60(6), 749-764. https://doi.org/10.1111/apt.18148
• Parikh, N. S., Wahbeh, F., Tapia, C., Ianelli, M., Liao, V., Jaywant, A., Kamel, H., Kumar, S., et al. (2024). Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease. BMJ Neurology Open, 6(1), e000543. https://doi.org/10.1136/bmjno-2023-000543
• Li, Y. S., Xia, Y. G., Liu, Y. L., Jiang, W. R., Qiu, H. N., Wu, F., Li, J. B., & Lin, J. N. (2024). Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: a two-sample mendelian randomization study. PLoS One, 19(2), e0297883. https://doi.org/10.1371/journal.pone.0297883
• Wang, J. Y., Bajaj, J. S., Wang, J. B., Shang, J., Zhou, X. M., Guo, X. L., Zhu, X., Meng, L. N., et al. (2019). Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. Journal of Digestive Diseases, 20(10), 547-556. https://doi.org/10.1111/1751-2980.12816
• Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 60(2), 715-735. https://doi.org/10.1002/hep.27210
• Bloom, P. P. (2025). The misdiagnosis and underdiagnosis of hepatic encephalopathy. Clinical and Translational Gastroenterology, 16(2), e00784. https://doi.org/10.14309/ctg.0000000000000784

Related reading

• Cognitive Screening in Primary Care: Add the Metabolic Picture
• MASLD in Primary Care: Screening When Liver Enzymes Look Normal
• Cognitive Assessment

Weight-Adjusted Waist Index: Stroke Risk Screening in Hypertension

In hypertensive adults aged 60 and older, a higher weight-adjusted waist index predicted new stroke after body mass index and waist circumference were already accounted for; the top quartile, an index of 10.80 or above, carried 1.87 times the stroke hazard of the bottom quartile.

Blood pressure visits record a cuff reading and a weight. The measurement that separates older hypertensive patients by stroke risk needs one more number, taken with a tape.

The weight-adjusted waist index is waist circumference in centimeters divided by the square root of body weight in kilograms, and in older adults with hypertension it predicts incident stroke after body mass index and waist circumference are already in the model. The hypertension visit records a cuff reading and a weight; the measurement that separates these patients by stroke risk needs a tape, and confirming what it means takes body composition analysis.

What the Xinjiang hypertension cohort found

The index was proposed in a Korean nationwide cohort of 465,629 subjects, where it showed the best predictive performance for cardiovascular mortality among the anthropometric measures tested. Its stroke signal in hypertension comes from a hospital-based cohort at the People’s Hospital of Xinjiang Uygur Autonomous Region in China: 4,962 hypertensive individuals aged 60 years or older with no prior stroke. Over a median follow-up of 3.2 years there were 547 new-onset strokes.

• Per standard deviation of the index, the adjusted hazard ratio for stroke was 1.30 (95% CI 1.18 to 1.42).
• The top quartile, an index of 10.80 or above, carried a hazard ratio of 1.87 against the bottom quartile.
• The model adjusted for body mass index, waist circumference, systolic and diastolic pressure, hypertension duration, diabetes, lipids, homocysteine, renal function, high-sensitivity C-reactive protein and antihypertensive, antidiabetic and lipid-lowering drugs.
• Adding the index to established risk factors moved the C-statistic from 0.534 to 0.575, and its area under the curve for stroke, 0.632, exceeded that of body mass index and waist circumference.

Mean body mass index was 22.37 in the lowest quartile and 25.93 in the highest. The patients carrying nearly double the stroke hazard were, by the scale, what most charts call mildly overweight at worst. This is a Chinese cohort, and the practice position is settled: a normal-BMI East Asian population is thin outside and fat inside, metabolically inflamed and insulin resistant. The bottom quartile is a reference group, not a healthy one, and the misclassified normal-weight patient is the subject of screening for the risk that BMI misclassifies.

Why a waist index sees what body mass index misses

Body mass index cannot tell muscle from fat, and waist circumference alone rises with overall size. Dividing waist by the square root of weight standardizes central adiposity for body size. The Xinjiang authors note the index is associated with a higher probability of having both high fat mass and low muscle mass, which is precisely the property that matters in geriatrics.

The non-obvious consequence is arithmetic. Weight sits in the denominator. An older patient who loses muscle loses weight, body mass index improves, the belt size barely moves, and the index climbs. The chart records success while the index records sarcopenic wasting under an unchanged abdominal depot. For years the reflex in most clinics, mine included, was to praise that weight loss in an older hypertensive patient. In a patient over 60, weight falling with a stable waist is a reason to measure composition, not to congratulate.

Two biological drivers carry the depot to the cerebral circulation. Visceral fat is an inflammatory organ: it sustains metaflammation, drives endothelial dysfunction and holds the patient in an insulin-resistant, proatherogenic state. Central adiposity also stokes sympathetic outflow and the renin-angiotensin system, which stiffens arteries, the change arterial stiffness testing quantifies, and makes pressure harder to control with every added drug. The third driver is structural. The hypertension visit is built around a cuff and a scale, waist circumference has no routine field in most workflows, and a food supply saturated with acellular carbohydrate and industrial seed oil builds the depot for years before weight crosses anyone’s threshold. In people rather than cohorts, the same depot shows up as aching in several places at once, covered in whether belly fat can cause chronic pain.

How the signal holds up in newer cohorts

Evidence from 2025 and 2026 carries the finding well beyond one Chinese hospital:

• UK Biobank, 2026. In 398,270 participants without prior stroke, the index had the strongest associations among the obesity measures compared. The top quartile carried hazard ratios for ischemic stroke of 1.25 in men and 1.36 in women, and the index beat body mass index for ischemic stroke discrimination in both sexes (men, C-statistic 0.712 versus 0.688; women, 0.748 versus 0.726).
• China Health and Retirement Longitudinal Study, 2025. Among 12,580 adults aged 45 and above, 727 had a stroke. The index predicted stroke in participants with hypertension (hazard ratio 1.13), and hypertension accounted for 12% of its total effect. Blood pressure control alone does not neutralize the depot.
• ACCORD, 2025. In type 2 diabetes the index predicted congestive heart failure with a hazard ratio of 1.20 per standard deviation, beyond stroke alone.

One disagreement belongs in the interpretation. The Xinjiang cohort reported an association with hemorrhagic stroke as well as ischemic stroke; in UK Biobank no significant association was observed for hemorrhagic stroke. The reproducible signal is ischemic. The Xinjiang data are single-region, rest on one baseline measurement and carry no physical activity or dietary data, which the authors state plainly. None of that weakens the case for measuring a waist. It limits how literally any one cut-off should be imported into a St. Louis panel. The same body composition lens has been turned on the brain, set out in how fat and muscle patterns relate to later dementia.

Who to screen and what a high index changes

• Adults aged 60 and older with hypertension, at every blood pressure visit, with waist measured by a consistent protocol.
• Hypertensive patients with a normal or modestly elevated body mass index, particularly East Asian and South Asian patients.
• Older patients whose weight is falling without a matching fall in waist circumference.
• Patients with diabetes, dyslipidemia or fatty liver whose blood pressure is controlled but whose global risk has not been reassessed.

Written selection criteria keep the list reproducible across clinicians.

A high index should not, on its own, push antihypertensive intensification in a frail patient. It relocates the patient into active vascular prevention and aims treatment at the depot and at muscle: food composition, resistance and walking programs, sleep and alcohol, each prescribed with its physiological rationale, with the index and body composition repeated to show whether the waist moved relative to weight. Where pressure control is being tightened in an older patient, the standing reading matters as much as the seated one, as set out in what a seated blood pressure reading misses.

What the measurements add

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service; it measures and reports to the ordering physician and does not treat. Waist and weight belong in every visit. What Measura adds is the physiology behind the index:

• Bioimpedance body composition separates fat mass from muscle mass, confirming whether a high index reflects abdominal fat, lost muscle or both.
• Arterial stiffness and endothelial function, the vascular consequence of the inflammatory depot and the substrate of ischemic stroke.
• Ankle-brachial index with toe-brachial measurement, for the systemic atherosclerosis that travels with cerebrovascular disease.
• Cardiac autonomic reflex tests, for the pressure and heart rate responses to standing and breathing that decide how safely a regimen can be tightened.

Standing orders and the wellness visit

A waist circumference is worthless unless it is taken the same way every time, so it belongs in standing orders rather than in the memory of whoever rooms the patient. The annual wellness visit already structures risk review, cognition and falls; recording the index there, beside composition and vascular findings, turns a single anthropometric number into a trajectory (see annual wellness visit integration). The documented measures this testing supports are covered in quality measures that cardiometabolic testing supports. Unmeasured is unmanaged, and a stroke risk hiding behind a normal body mass index is the most unmanaged risk in the room.

Frequently asked questions

References

• Hu, J., Cai, X., Song, S., Zhu, Q., Shen, D., Yang, W., Hong, J., Luo, Q., et al. (2024). Association between weight-adjusted waist index with incident stroke in the elderly with hypertension: a cohort study. Scientific Reports, 14(1), 25614. https://doi.org/10.1038/s41598-024-76709-y
• Park, Y., Kim, N. H., Kwon, T. Y., & Kim, S. G. (2018). A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. Scientific Reports, 8(1), 16753. https://doi.org/10.1038/s41598-018-35073-4
• Li, F., Wang, Z. Y., Qi, S. S., Xu, Y. M., & Shi, C. H. (2026). Predictive value of traditional and novel obesity indices for stroke and its subtypes across sexes and glucose status: toward precision prevention strategies. Journal of the American Heart Association, 15(6), e043083. https://doi.org/10.1161/JAHA.125.043083
• Xu, F., Liu, H., Li, M., Zhang, M., Chen, X., & Hou, M. (2025). Hypertension mediates the association between weight-adjusted waist index and new onset stroke risk in middle-aged and older Chinese adults: evidence from the CHARLS study. Frontiers in Neurology, 16, 1587176. https://doi.org/10.3389/fneur.2025.1587176
• Liu, M., Pei, J., Zeng, C., Xin, Y., Tang, P., & Hu, X. (2025). Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. Nutrition Journal, 24(1), 184. https://doi.org/10.1186/s12937-025-01251-0
• Wang, J., Zhu, A., Zeng, R., Chen, L., Xie, F., Zhu, K., Fan, T., Ye, D., et al. (2025). A J-shaped association between weight-adjusted waist index and cardiovascular disease: a longitudinal study from the CHARLS database. BMC Public Health, 25(1), 4041. https://doi.org/10.1186/s12889-025-25127-4

Related reading

• Visceral Adiposity: Screening for the Risk That BMI Misclassifies
• Orthostatic Blood Pressure: What a Seated Reading Misses
• Bioimpedance Body Composition

The Cholinergic Anti-Inflammatory Pathway: What You Can Measure

The cholinergic anti-inflammatory pathway is acetylcholine switching off TNF release from macrophages through the alpha-7 receptor, a finding mapped in mice rather than people. What a practice can document is autonomic, vascular, cardiometabolic, body-composition and cognitive function in the same patient; motility and disease activity belong to gastroenterology.

Patients bring this pathway to clinic as a question about nicotine. The receptor biology is real, the delivery question is unanswered, and the measurable part of it sits outside the colon.

The cholinergic anti-inflammatory pathway usually reaches a clinic as a question, not a prescription. A patient whose distal ulcerative colitis surfaced eleven months after she stopped smoking asks whether she should start again, and nobody has answered her, because the honest sentence sounds like an endorsement of tobacco. The answer is no. The useful work is separating three claims that get merged: an immune receptor, a motor receptor and a delivery route. The video above closes The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes.

The cholinergic anti-inflammatory pathway: two receptors, two arguments

The immune arm is better mapped and it is not human. Acetylcholine cannot switch off macrophage TNF release without the alpha-7 subunit, and in mice bred without it the vagal suppression of TNF disappears entirely. In an inflamed gut wall it sits on monocytes and macrophages rather than neurons. Rodent work throughout.

Fast transmission between enteric neurons runs on a different assembly: blocking the alpha-3-beta-4 type drops evoked responses, while an alpha-7 antagonist had no effect at any developmental age. Motor and immune actions are separable, and evidence that looks contradictory stops conflicting once sorted that way.

The human anchor is thinner and more interesting than either. Surgical colon answered a nicotinic stimulus with action potentials in 51 neurons, drawn from 20 myenteric ganglia in 19 patients and bursting 2 to 23 times near 5.3 Hz, while only about 8% of the myenteric neurons responded at all, which the authors call low. The same tissue bank puts myenteric density near 84 neurons per square millimeter in sigmoid and rectum against 38 in the ascending colon: twice the wiring, where distal disease sits.

What the trials support, and where the ceiling is

Pooled data put transdermal nicotine ahead of placebo for inducing remission. Then the ceiling, from the same review: against prednisone or mesalamine, no advantage. A broader meta-analysis found no efficacy, with a relative risk of 1.40 whose interval crosses one, and harm at 1.95. Harm replicated where benefit did not.

The randomized rectal route used a 6 mg liquid preparation and failed, with remission at 27% against 33% on placebo and the authors calling the enemas well tolerated but not efficacious. Tolerability was the one problem local delivery solved: one of 104 patients stopped for harm.

The position, stated exactly. The formulation is the claim: a small dose held against the distal colonic mucosa, not a whole patient dosed through the skin. No published trial of a nicotine suppository exists, in any indication, anywhere; the group that built such formulations assayed release in a dish and stopped there. A failed patch and a failed liquid enema are not evidence against a preparation nobody has administered, and an untested preparation is not a proven one. None of this is a reason for a patient to use nicotine in any form.

On motility, keep two claims apart. The evacuation claim is supported in humans: transient high-amplitude propagated contractions and faster colonic transit followed a high dose in healthy subjects, mass peristalsis recorded rather than inferred from a receptor map. The migrating motor complex claim is not, and no controlled human trial of nicotine for a stalled motor complex exists. Motility studies are not in this test library; they belong to gastroenterology, with endoscopy and stool markers.

Three measurement failures worth carrying into your own practice

First, the tissue was never sampled. No study has measured nicotine concentration in rectal mucosal tissue, so the local-delivery premise is inferred from serum. A mechanism assayed one compartment away from where it supposedly acts is a hypothesis, not a demonstration.

Second, the level did not predict the patient. In the liquid enema pilot, 4 of 10 patients had adverse events while serum nicotine was low or undetectable. Managing by concentration would have missed all of them.

Third, a dosing signal sat unused in an adverse-event table. In the carbomer enema study the subjects who reported side effects were all female lifelong nonsmokers of low body weight, and inflamed bowel absorbed the dose more slowly, peaking at 60 minutes against 45. Exposure scales to the compartment holding it, which body weight alone does not describe.

Who to test, what changes, and how the baseline is captured

Measura [Cardiometabolic and Autonomic Health Analysis] measures cardiometabolic and autonomic function. It does not treat, and it does not grade disease activity in a bowel. What it documents is the physiology a cholinergic drug discussion assumes and nobody records.

• Autonomic nervous system testing and cardiac autonomic reflex tests record how heart rate and blood pressure answer standardized challenges, which makes a later change interpretable instead of anecdotal.
• Heart rate variability quantifies beat-to-beat variation. It measures tone, not a receptor or a cytokine, and should never be presented as either.
• Arterial stiffness and endothelial function measures vessel behavior directly, where older trials reached for a circulating marker of endothelial damage.
• Laboratory panels carry the acute-phase and metabolic markers you select.
• Bioimpedance body composition separates lean from fat mass, the compartment that adverse-event table pointed at when the lightest patients fared worst.

What a finding changes is modest and concrete. An autonomic or vascular abnormality documented before a cessation program, or before any drug with cholinergic or sympathomimetic effects, becomes the comparator for everything after it. Without one, a later symptom has nothing to be measured against.

Workflow decides whether any of this happens. Standing orders capture a baseline without a fresh decision at every visit, the annual wellness visit is the natural slot, and getting results into the record turns a study into documentation that supports MIPS and HEDIS quality reporting. In older patients the same visit documents cognitive assessment and fall prevention, and selection criteria keep testing pointed where a result changes something. The patient-facing version is what your patients are reading.

The strongest case against all of it

The strongest argument is not danger. It is that the molecule has had its chance: four preparations, two groups, three decades, harm replicating and benefit not. The 6 mg liquid vehicle is done, and so is the patch as monotherapy.

What does not follow is that one dose in one vehicle settles a route, particularly when that trial never recorded how long its own enemas stayed in, and when 3 of 10 patients in an earlier pilot quit inside a week, unable to retain the liquid. One caution runs against my own reading: some blood leaving the lower rectum skips the liver altogether, so a preparation sitting low could put more drug per milligram into the rest of the patient, not less. Unmeasured either way.

The honest mechanistic route runs away from the molecule. Rats with postoperative ileus were given a serotonin receptor agonist, which pushed cholinergic neurons to release more acetylcholine and quieted the macrophages of the muscle layer; ganglionic blockade, or an alpha-7 antagonist, abolished it, and motility and white-cell infiltration improved together. Rodent data, and the effective drug was serotonergic. No nicotinic agonist has ever been developed as a gut prokinetic.

So the instruction is unchanged. Counsel against resuming smoking, document the interval from quit date to diagnosis, offer no nicotine, and do not let the awkwardness of the question substitute for an answer: a patient who carries it alone for two years has been managed by silence. Rescue is not repair. Every study named here sits with its limits in the companion deep dive, and specialty applications covers where this fits by discipline.

Frequently asked questions

References

• Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C. J., & Tracey, K. J. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 421(6921), 384-388. https://doi.org/10.1038/nature01339
• Elfers, K., Sehnert, A. S., Wagner, A., Zwirner, U., Linge, H., Kulik, U., Poehnert, D., Winny, M., Gundert, B., Aselmann, H., & Mazzuoli-Weber, G. (2024). Functional and structural investigation of myenteric neurons in the human colon. Gastro Hep Advances, 4(1), 100537. https://doi.org/10.1016/j.gastha.2024.08.016
• Foong, J. P. P., Hirst, C. S., Hao, M. M., McKeown, S. J., Boesmans, W., Young, H. M., Bornstein, J. C., & Vanden Berghe, P. (2015). Changes in nicotinic neurotransmission during enteric nervous system development. The Journal of Neuroscience, 35(18), 7106-7115. https://doi.org/10.1523/JNEUROSCI.4175-14.2015
• Tsuchida, Y., Hatao, F., Fujisawa, M., Murata, T., Kaminishi, M., Seto, Y., Hori, M., & Ozaki, H. (2011). Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut, 60(5), 638-647. https://doi.org/10.1136/gut.2010.227546
• McGrath, J., McDonald, J. W. D., & Macdonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews(4), CD004722. https://doi.org/10.1002/14651858.CD004722.pub2
• Nikfar, S., Ehteshami-Ashar, S., Rahimi, R., & Abdollahi, M. (2010). Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clinical Therapeutics, 32(14), 2304-2315. https://doi.org/10.1016/j.clinthera.2011.01.004
• Ingram, J. R., Thomas, G. A. O., Rhodes, J., Green, J. T., Hawkes, N. D., Swift, J. L., Srivastava, E. D., Evans, B. K., Williams, G. T., Newcombe, R. G., Courtney, E., & Pillai, S. (2005). A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology, 3(11), 1107-1114. https://doi.org/10.1016/s1542-3565(05)00849-9
• Coulie, B., Camilleri, M., Bharucha, A. E., Sandborn, W. J., & Burton, D. (2001). Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Alimentary Pharmacology & Therapeutics, 15(5), 653-663. https://doi.org/10.1046/j.1365-2036.2001.00959.x
• Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Lawson, G. M., Zins, B. J., Compton, R. F., Mays, D. C., Lipsky, J. J., Batts, K. P., Offord, K. P., Hurt, R. D., & Green, J. (1997). Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study. Alimentary Pharmacology & Therapeutics, 11(4), 663-71. https://doi.org/10.1046/j.1365-2036.1997.00208.x
• Green, J. T., Thomas, G. A., Rhodes, J., Evans, B. K., Russell, M. A., Feyerabend, C., Fuller, G. S., Newcombe, R. G., & Sandborn, W. J. (1997). Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis. Clinical Pharmacology and Therapeutics, 61(3), 340-8. https://doi.org/10.1016/S0009-9236(97)90167-3

Related reading

• Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier
• Autonomic Nervous System Testing

Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier

Low dose naltrexone works indirectly, through a chain of four links: a rebound rise in beta-endorphin, intermittent rather than continuous receptor blockade, effects on lymphocytes and regulatory T cells, and antagonism of Toll-like receptor 4. It is not a mast cell stabilizer.

The low-dose naltrexone mechanism most often repeated is the one the pharmacology does not support. The one that survives is indirect, upstream, and graded link by link.

Ask ten clinicians for the low dose naltrexone mechanism of action and several will call it a mast cell stabilizer. It is not, and the error matters because it sets the wrong expectations and the wrong endpoints. The mechanism that holds up is a chain of four links, each resting on a different grade of evidence.

The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes applies that chain, in the chapter video She’s Not Allergic to Her Food. She’s Fermenting It., to a patient with gut-predominant mast cell symptoms. Measura [Cardiometabolic and Autonomic Health Analysis] reports objective measurements to the clinician who orders them and neither diagnoses, treats nor prescribes. The pharmacology below is for interpretation and co-management, not a recommendation to start or change any drug.

Link one: the rebound, measured in human CSF

The therapeutic event is the rebound, not the blockade. At a standard rather than low dose, naltrexone raised cerebrospinal fluid beta-endorphin from 1.15 to 2.03 fmol/mL while POMC did not move, so the beta-endorphin-to-POMC ratio rose 80%, holding after two and seven days. Two details inside that study bear on patient selection. Among fourteen healthy volunteers, overweight and obese subjects showed a 138% increase versus 52.1% for the lean group, so the metabolically loaded patient may mount the larger response. And plasma cortisol rose from 12.4 to 15.6 µg/dL, a 28% increase. A drug that lifts endorphin and cortisol together is not a clean intervention.

Link two: duration of blockade, not dose

Three decades of laboratory work converge on one principle: intermittent blockade at low doses depressed cell replication, while continuous blockade at high doses enhanced it. The full 100 mg dose occupies 92% of kappa receptors on PET, and in that alcohol-use cohort higher occupancy went with more craving, not less. Occupancy in the 1.5 to 4.5 mg range has never been imaged in humans. The main metabolite, 6beta-naltrexol, is itself an antagonist with a terminal half-life of 11.1 hours, so whether a bedtime dose is still intermittent by morning is unmeasured. That is the gap in the dose rationale, stated plainly.

Link three: lymphocytes and Tregs

Of the four, this link carries the weakest evidence. Whether immune cells express opioid receptors is contested, with some groups confirming mRNA and protein and others finding no message. In female mice, regulatory T cells produced enkephalin that engaged sensory-neuron delta opioid receptors and dampened nociception, a function separable from immunosuppression and dependent on sex hormones. Tregs and the opioid system are coupled; the direction of traffic in humans is not established. The widely quoted sentence that endorphins bind Tregs to reduce cytokines traces to a single case report in which one patient received naltrexone, immunoglobulin and antibiotics together.

Human data are limited to downstream output. Following an eight-week course in eight women with fibromyalgia, eighteen plasma mediators fell, including IL-1β, IL-6, IL-17A and TNF-α, with pain down 15%. Anti-inflammatory mediators such as IL-10 fell too, and no multiplicity correction was described. It is a signal, not a clean anti-inflammatory effect.

Link four: TLR4, stated narrowly

Naltrexone and naloxone antagonize Toll-like receptor 4, the lipopolysaccharide receptor. In the defining experiment all four isomers, including the clinical (−)-naltrexone, attenuated LPS-induced signaling in a cell line by non-competitive inhibition, but the microglial and animal work used the (+)-isomers and (−)-naloxone. Naltrexone shows no stereoselectivity at TLR4, which is why the clinical isomer works at all, and it is weak, roughly 25 times less potent than an optimized bivalent ligand. The (+)-isomers inhibited nitric oxide and TNF-α but not IL-1β, and not NF-κB, p38 or JNK signaling; the blocked arm was TRIF-IRF3-interferon. No human study has shown low-dose naltrexone antagonizing TLR4. The tier is cellular and animal.

MRGPRX2: why it is not a stabilizer

Opioids degranulate mast cells through MRGPRX2, outside the classical opioid system. Naltrexone is inactive there, neither agonist nor antagonist, and naloxone at 10 µM did not alter opioid-induced degranulation in a human mast cell line. In the animal spinal mass model, scores were 2.3 with morphine and 2.5 with morphine plus naltrexone, while cromolyn blocked the damage. None of that contradicts the chain above. The route is indirect and upstream: endorphin rebound acting on the lymphocyte compartment, and TLR4 antagonism thinning the cytokine traffic that keeps mucosal mast cells primed. Quieting follows without the drug touching the mast cell membrane.

Low dose naltrexone mechanism of action in the clinical record

• Crohn’s disease, randomized: two trials, 46 participants. Remission 30% against 18%, not significant; 70-point response 83% against 38%, significant; endoscopic response 72% against 25%. GRADE low for imprecision.
• Fibromyalgia, randomized: four trials, 222 patients, pooled pain reduction of −0.86 points; the largest trial, 6 mg for twelve weeks, missed its primary endpoint.
• IBS: open-label only, 0.5 mg daily, global improvement in 76% of 42 patients.
• Practice-level data: a survey of 553 patients rated benefit 5.6 of 10, equal to benzodiazepines and below antihistamines at 6.3; a dysautonomia chart review found no significant change on a validated autonomic instrument, with pain improvement documented in 24.14%.

Where objective measurement fits

Tryptase, histamine and mast cell testing are specialized studies done elsewhere; Measura does not run them beyond general laboratory panels. Under the restrictive consensus, normal serum tryptase is 0 to 11.4 ng/mL and an episode is defined by tryptase exceeding 1.2 times baseline plus 2 ng/mL, and every one of the three criteria is required.

What Measura can document is the comorbid terrain. Orthostatic intolerance was the prescribing reason in 27.78% of that dysautonomia review, and the null there was on a questionnaire. Two biological drivers keep this population primed, endotoxin crossing a damaged barrier and metaflammation in the first brain, and one structural one: every comorbidity is an exclusion criterion somewhere, so the trial population never matches the clinic. Objective baselines help close that gap:

• Autonomic nervous system testing and cardiac autonomic reflex tests document orthostatic and reflex responses before and during any therapy the treating physician chooses.
• Heart rate variability records vagal tone as a repeatable number.
• Bioimpedance body composition characterizes adiposity, relevant given the larger rebound seen in overweight and obese subjects.

Selection and ordering are covered under clinical selection criteria and specialty applications. The patient version of this topic is here, the autonomic overlap is developed in orthostatic intolerance screening, and the study-level limits are in the Chapter 31 Deep Dive.

Frequently asked questions

References

• Gordon, R. J., Panigrahi, S. K., Meece, K., Atalayer, D., Smiley, R., & Wardlaw, S. L. (2017). Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans. Journal of the Endocrine Society, 1(10), 1235-1246. https://doi.org/10.1210/js.2017-00289
• McLaughlin, P. J., & Zagon, I. S. (2015). Duration of opioid receptor blockade determines biotherapeutic response. Biochemical Pharmacology, 97(3), 236-246. https://doi.org/10.1016/j.bcp.2015.06.016
• de Laat, B., Nabulsi, N., Huang, Y., O’Malley, S. S., Froehlich, J. C., Morris, E. D., & Krishnan-Sarin, S. (2020). Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Molecular Psychiatry, 26(9), 5053-5060. https://doi.org/10.1038/s41380-020-0811-8
• Midavaine, E., Moraes, B. C., Benitez, J., Rodriguez, S. R., Braz, J. M., Kochhar, N. P., Eckalbar, W. L., Tian, L., Domingos, A. I., Pintar, J. E., Basbaum, A. I., & Kashem, S. W. (2025). Meningeal regulatory T cells inhibit nociception in female mice. Science, 388(6742), 96-104. https://doi.org/10.1126/science.adq6531
• Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016
• Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29. https://doi.org/10.1111/j.1460-9568.2008.06321.x
• Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology, 173(5), 856-869. https://doi.org/10.1111/bph.13394
• Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., Shoichet, B. K., & Roth, B. L. (2017). In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 13(5), 529-536. https://doi.org/10.1038/nchembio.2334
• Parker, C. E., Nguyen, T. M., Segal, D., MacDonald, J. K., & Chande, N. (2018). Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 4(4), CD010410. https://doi.org/10.1002/14651858.CD010410.pub3
• Zapata, N., Georgiadi, E., Cantrell, C., Rilinger, R. G., Levine, M. A., & Wilson, R. (2025). Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia. Cureus, 17(6), e86538. https://doi.org/10.7759/cureus.86538

Related reading

• Patient Activation Measure: Why Maintenance Needs Objective Re-Testing
• The Cholinergic Anti-Inflammatory Pathway: What You Can Measure
• Autonomic Nervous System Testing

Patient Activation Measure: Why Maintenance Needs Objective Re-Testing

Patient activation measure scores related to 12 of 13 outcomes in 25,047 primary care patients, but lifestyle results decay as treatment intensity falls, so maintenance needs objective metabolic re-testing on a fixed schedule. Set a baseline at the end of the intensive phase and write a defined repeat date into the order.

Every long lifestyle trial draws the same curve: intensity decays and the result decays with it. A practice cannot hold intensity constant, but it can standardize what gets re-measured and when.

Scores on a patient activation measure predict outcomes that the ritual of consultation does not, and the durability literature explains why that matters for the maintenance phase. Lifestyle treatment works while it is delivered at dose and erodes as the dose falls. The one variable a practice fully controls in year two is whether anyone is measuring the erosion.

The video There Is No Discharge Date, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, frames maintenance as an agricultural job rather than a curative one. Measura [Cardiometabolic and Autonomic Health Analysis] measures and reports to whoever ordered the testing, and diagnosis and treatment stay with that clinician. What follows is the screening and re-testing logic that framing implies.

The durability record, read for its design

The original prevention trial enrolled 3,234 nondiabetic adults with impaired glucose tolerance, mean age 51, mean BMI 34.0, 68 percent women and 45 percent from minority groups, followed for an average of 2.8 years. A 7% weight-loss target plus 150 minutes of weekly activity cut incidence by 58%, against 31% for metformin. The winning arm was an individually delivered curriculum with case managers, not advice.

The fifteen-year follow-up retained 2,776 participants, 88% of the surviving cohort. Cumulative incidence converged to 55%, 56% and 62%, with a hazard ratio of 0.73 for lifestyle, and the aggregate microvascular outcome did not separate by arm. Two design facts govern interpretation. After the randomized phase every participant was offered lifestyle training, so the comparison is of initial assignment rather than maintained regimens. And protection followed the achieved outcome: those who avoided diabetes by any route had 28% fewer microvascular complications. In women, lifestyle carried a microvascular prevalence of 8.7% against 11.0% on placebo and 11.2% on metformin, a subgroup finding measured once at study end.

Look AHEAD randomized 5,145 overweight or obese adults with type 2 diabetes, median follow-up 9.6 years and maximum 13.5, and stopped for futility on the cardiovascular endpoint. The intensive arm still improved glycated hemoglobin, fitness and every risk factor except LDL cholesterol, while the comparison arm also lost weight and pharmacotherapy improved in both. It tested calorie restriction and activity, not diet quality. A null on that question is not a null on terrain repair.

Outside trials, the national prevention program enrolled 14,747 adults. Participants reported a weekly average of 152 minutes of activity, median 128, with 41.8% meeting the 150-minute goal, and weight loss rose with sessions attended. The authors named retention as the fix.

Patient activation measure scores versus consultation

In 25,047 insured primary care patients scored once and matched to their records, activation related to 12 of 13 outcomes across prevention, unhealthy behaviors, clinical indicators and utilization. The design is cross-sectional in one health system, so activation may partly report good health rather than produce it.

Shared decision-making, studied in 396 patients with COPD or asthma, showed no association with medication adherence, an odds ratio of 1.01, with complete adherence at 41.2%. The mean score on the decision-making instrument was 26.7 on a scale running to 45, which leaves little room to detect an effect. Consulted and capable are different states, and neither study tested teaching a patient the mechanism of their own disease. Objective, repeated numbers are one concrete way to build that capability: a patient who can read a trend can adjust before the next visit.

Why the terrain argues for individual re-measurement

Two upstream biological drivers set the maintenance problem. The first is the microbial community of the first brain, the gut. In the seventeen-week feeding trial, 39 adults were assigned and 18 per arm analyzed; high-fiber eaters split into three distinct immune trajectories sorted by baseline microbiota diversity. In 800 people across 46,898 meals, glycemic responses to identical food varied widely, and a model integrating blood parameters, anthropometrics, activity and microbiota was checked in an independent 100-person cohort. In mice held on low fiber for four generations, 141 of 208 taxa did not return with fiber alone. The second driver is metaflammation and insulin resistance, which drift silently while weight looks stable. The third is structural: programs designed around attendance lose the dose, and the patient absorbs the cost in disease.

Heterogeneous response plus decaying intensity means a population protocol cannot tell you which patient is slipping. A measured baseline and scheduled repeats can.

What to re-measure, and what a finding changes

• Laboratory panels: glycemic markers, fasting insulin and lipids. A rising insulin requirement at stable weight is an indication to intensify behavioral support before glucose crosses a threshold.
• Bioimpedance body composition: separates fat regain from lean loss, which weight alone conflates.
• Indirect calorimetry: measured resting energy expenditure after substantial loss, replacing a predictive equation when setting intake targets.
• Sudomotor testing: sweat-gland function of small nerve fibers in the hands and feet, relevant because neuropathy sat inside the aggregate microvascular outcome.
• Heart rate variability: a documented autonomic baseline for patients whose vagal tone is part of the plan.

Liver histology is a different study done elsewhere, though it makes the dose point cleanly: among patients with biopsy-confirmed NASH who lost at least 10% of body weight, 90% resolved and 45% had fibrosis regress. In older patients, the year-long Mediterranean trial in 612 adults aged 65 to 79 linked adherence-favored organisms to less frailty and better cognition, which makes a cognitive assessment baseline and fall-prevention pairing reasonable in the same encounter.

Workflow and documentation

A standing order keyed to completion of an intensive lifestyle phase removes the dependence on someone remembering to re-test; the logic is laid out in making screening reproducible. Between visits, the chronic care and monitoring structure carries the trend. Record the selection criterion, the baseline values and the planned re-measure date together so change is interpretable and supports quality reporting. The prevention-program piece for physicians is diabetes prevention program screening, the patient version of this topic is here, and the study-level limits are in the Chapter 30 Deep Dive. The next physician article covers the low-dose naltrexone mechanism of action.

Frequently asked questions

References

• Greene, J., & Hibbard, J. H. (2012). Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med, 27(5), 520-6. https://doi.org/10.1007/s11606-011-1931-2
• Achterbosch, M., Vart, P., van Dijk, L., & van Boven, J. F. M. (2023). Shared decision making and medication adherence in patients with COPD and/or asthma: the ANANAS study. Front Pharmacol, 14, 1283135. https://doi.org/10.3389/fphar.2023.1283135
• Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512
• Diabetes Prevention Program Research Group. (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol, 3(11), 866-75. https://doi.org/10.1016/S2213-8587(15)00291-0
• Wing, R. R., Bolin, P., Brancati, F. L., Bray, G. A., Clark, J. M., Coday, M., Crow, R. S., Curtis, J. M., Egan, C. M., Espeland, M. A., Evans, M., Foreyt, J. P., Ghazarian, S., Gregg, E. W., Harrison, B., Hazuda, H. P., Hill, J. O., Horton, E. S., Hubbard, V. S., … Yanovski, S. Z. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 369(2), 145-54. https://doi.org/10.1056/NEJMoa1212914
• Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017). A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care, 40(10), 1331-1341. https://doi.org/10.2337/dc16-2099
• Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., Robinson, J. L., Elias, J. E., Sonnenburg, E. D., Gardner, C. D., & Sonnenburg, J. L. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell, 184(16), 4137-4153.e14. https://doi.org/10.1016/j.cell.2021.06.019
• Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador, D., Avnit-Sagi, T., Lotan-Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalova, L., Pevsner-Fischer, M., … Segal, E. (2015). Personalized Nutrition by Prediction of Glycemic Responses. Cell, 163(5), 1079-1094. https://doi.org/10.1016/j.cell.2015.11.001
• Sonnenburg, E. D., Smits, S. A., Tikhonov, M., Higginbottom, S. K., Wingreen, N. S., & Sonnenburg, J. L. (2016). Diet-induced extinctions in the gut microbiota compound over generations. Nature, 529(7585), 212-5. https://doi.org/10.1038/nature16504
• Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 149(2), 367-78.e5. https://doi.org/10.1053/j.gastro.2015.04.005

Related reading

• Intestinal Permeability Test: Endpoints for a Stalled Gut Protocol
• Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier
• Laboratory Panels